Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.

ABSTRACT:

Introduction

Significant gains in advanced melanoma have been made through immunotherapy trials. Factors influencing equitable access and survival impact of these novel therapies are not well-defined.

Method

Retrospective analysis using National Cancer Database of patients with advanced stage III and IV melanoma from 2004 to 2021. Multivariable logistic regression was used to study the use of immunotherapy and Cox proportional hazard regression to evaluate overall survival (OS).

Results

47,427 patients with increasing utilization of immunotherapy from 13.78% in 2004 to 65.88% by 2021. Inequitable adoption were impacted by age, sex, socioeconomic status/affordability, insurance types and residential educational/income level. Receiving immunotherapy was associated with

SUBMITTER: Ali MS 

PROVIDER: S-EPMC11834448 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature